Sharon Winer
Reproductive Endocrinology · Beverly Hills, CANPI 1821456229
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $356,457 of the $449,353 with a category attached, or 79.3%. 11 manufacturers reported payments, led by Mayne Pharma Commercial LLC at 36.4% of the total. Reporting peaked in 2019 at $218,957 and has fallen 75.6% since, to $53,400 in 2025. Among reproductive endocrinology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 506 payments — averaging $888.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mayne Pharma Commercial LLC$164K
- AbbVie$134K
- Therapeuticsmd, Inc.$88K
- Astellas Pharma US Inc$63K
- Lupin Inc.$700
- Coopersurgical, Inc.$169
- plus $234 from 5 others
What the payments were for
- Consulting fees$7000%
- Speaking & faculty fees$356,45779%
- Travel & lodging$78,55917%
- Food & beverage$13,5583%
- Education$790%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mayne Pharma Commercial LLC | 119 | $163,619 |
| AbbVie | 193 | $133,849 |
| Therapeuticsmd, Inc. | 125 | $88,196 |
| Astellas Pharma US Inc | 61 | $62,587 |
| Lupin Inc. | 1 | $700 |
| Coopersurgical, Inc. | 1 | $169 |
| Novo Nordisk | 1 | $121 |
| AMAG Pharmaceuticals, Inc. | 2 | $64 |
| Bayer | 1 | $17 |
| Myovant Sciences Inc. | 1 | $16 |
| Astellas Pharma Global Development | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$449,353 in reported general payments places this provider in the 95th percentile of 230 reproductive endocrinology providers in California.
See all reproductive endocrinology providers in California →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 41 | $5,315 |
| MenostarEstradiol | 14 | $4,955 |
| Estradiol (Twice Weekly)Estradiol | 24 | $3,178 |
| PremarinEstrogens, Conjugated | 11 | $2,822 |
| Estradiol (Once Weekly)Estradiol | 17 | $1,498 |
| ProgesteroneProgesterone, Micronized | 41 | $1,456 |
| ValacyclovirValacyclovir Hcl | 17 | $956 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerMenostar | $17 | $4,95514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 230 reproductive endocrinology providers in California.
Other reproductive endocrinology in Beverly Hills
- Shahin GhadirBeverly Hills$31K
- Alin AkopiansBeverly Hills$11K
- Sanjay Agarwalla Jolla$262K
- Valerie FloresSan Diego$184K
- Monica PasternakSan Francisco$77K
- Linda GiudiceSan Francisco$67K
- Valerie BakerSan Jose$66K
- Lisa BechtNewport Beach$48K
- Alexander QuaasSolana Beach$40K
- Donna ShoupeLos Angeles$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.